Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

LeMaitre attracts corporate heavyweight to board, audit group

This article was originally published in Clinica

Executive Summary

LeMaitre Vascular (Burlington, Massachusetts), a developer and manufacturer of devices for the treatment of peripheral vascular disease, has appointed John O’Connor to its board of directors; he will also serve as chair of the company’s audit committee. Mr O’Connor retired in 2006, before which he was vice-chairman of services for PricewaterhouseCoopers, where he was a partner for 24 years. The appointment should enable LeMaitre to "regain compliance with the Marketplace Rules of the Nasdaq Stock Market, which require that a majority of the company’s board of directors be independent and that the company’s audit committee be composed of three or more independent directors”. Mr O’Connor’s “strategic acumen” will be an “ideal complement” to those of other board members, said chairman and CEO George LeMaitre.

You may also be interested in...



Asia Regulatory Forum Update

Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.

Saudi Arabia adopts interim device authorisation regulation

Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.

Canada takes action to increase more adverse event reporting

The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT042054

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel